Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

<p>Abstract</p> <p>Background</p> <p>Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fabi Alessandra, Russillo Michelangelo, Ferretti Gianluigi, Metro Giulio, Nisticò Cecilia, Papaldo Paola, De Vita Ferdinando, D’Auria Giuliana, Vidiri Antonello, Giannarelli Diana, Cognetti Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2012-10-01
Colecção:BMC Cancer
Assuntos:
Maintenance Bevacizumab
Antiangiogenic agents
HER2 negative metastatic breast cancer
Acesso em linha:http://www.biomedcentral.com/1471-2407/12/482
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados